Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
ADARx Pharmaceuticals, Inc.
Last 30 daysInsiders bought $87.75M · 5 buyers, led by Sr One Capital Management (10% owner) with $27.2M. No qualifying insider sales.
This reflects the filings imported so far, not a complete trading history.
Show all loaded activityThis reflects the filings imported so far, not a complete trading history.
$87,745,772 of common-equity purchase value after transaction-age decay across 180 days.
5 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.
5 buying groups inside 30 transaction-date days, public by the snapshot cutoff.
At least one row increased reported same-security holdings by 10% or established a new reported position; indirect interests may overlap.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.